Rebentisch, the company’s US chief operations officer, has taken the reins from Brayden Sutton
Inc () (OTCQX:TGIFF) is revamping its executive team, including the selection of a new CEO.
Chris Rebentisch, the cannabis wellness company’s US chief operations officer, has taken the reins from Brayden Sutton. Sutton will remain chairman of the board.
Rebentisch founded Infused MFG, a 1933 subsidiary, and developed the intellectual property for its Canna Hemp brand. He has also overseen Alternative Medicine Association, the company’s tetrahydrocannabinol (THC) subsidiary.
READ: 1933 Industries subsidiary sells, then leases back Las Vegas cultivation site
Additionally, Steve Radusch was named chief financial officer, replacing Ryan Maarschalk, and Terry Taouss was appointed to the board, stepping in for the outgoing Andrew Richards.
Radusch most recently served as CFO of a licensed cannabis company in Nevada, and he brings more than 25 years of financial operations, cash management and other related experience. He was CFO of a tech startup where he led a capital raise, as well as acting CFO for a $100 billion-plus and a $7 billion Fortune 500 company. His appointment is effective June 17.
Taouss is currently a principal of advertising technology company AdProfs, and he previously worked as president of cannabis financing company He also was part of the founding management team at SiteScout, another ad tech company.
Separately, Alternative Medicine Association was granted a temporary occupancy permit for its cultivation facility. The company is also expanding its extraction capacity to more than 14,000 square feet from 5,000 square feet.
"As the first entrant into the legal cannabis market in Las Vegas, we have been able to leverage our early mover advantage to establish our brand, secure our distribution and gain market share,” Rebentisch said. “We are the largest single supplier of branded goods in Nevada and sell our CBD line in 46 states.”
Shares of the British Columbia company fell 4% to C$0.48 on the CSE and 3.5% to US$0.36 on OTC markets.
Contact Andrew Kessel at [email protected]
Follow him on @andrew_kessel